161 related articles for article (PubMed ID: 23249376)
1. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Bioconjug Chem; 2013 Jan; 24(1):97-104. PubMed ID: 23249376
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2012 Oct; 40(10):2021-5. PubMed ID: 22822036
[TBL] [Abstract][Full Text] [Related]
3. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
Pardridge WM; Boado RJ; Giugliani R; Schmidt M
BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294
[TBL] [Abstract][Full Text] [Related]
4. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
Boado RJ; Ka-Wai Hui E; Zhiqiang Lu J; Pardridge WM
Biotechnol Bioeng; 2014 Nov; 111(11):2317-25. PubMed ID: 24889100
[TBL] [Abstract][Full Text] [Related]
5. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
[TBL] [Abstract][Full Text] [Related]
6. Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein.
Boado RJ; Pardridge WM
Mol Pharm; 2017 Apr; 14(4):1271-1277. PubMed ID: 28279069
[TBL] [Abstract][Full Text] [Related]
7. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
J Biotechnol; 2009 Oct; 144(2):135-41. PubMed ID: 19735678
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
Boado RJ; Hui EK; Lu JZ; Sumbria RK; Pardridge WM
Bioconjug Chem; 2013 Oct; 24(10):1741-9. PubMed ID: 24059813
[TBL] [Abstract][Full Text] [Related]
9. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.
Lu JZ; Boado RJ; Hui EK; Zhou QH; Pardridge WM
Biotechnol Bioeng; 2011 Aug; 108(8):1954-64. PubMed ID: 21351076
[TBL] [Abstract][Full Text] [Related]
10. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
11. Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Mol Pharm; 2016 Sep; 13(9):3241-6. PubMed ID: 27513815
[TBL] [Abstract][Full Text] [Related]
12. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2014 Aug; 11(8):2928-34. PubMed ID: 24949884
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.
Pardridge WM; Boado RJ
Pharm Res; 2009 Oct; 26(10):2227-36. PubMed ID: 19609743
[TBL] [Abstract][Full Text] [Related]
15. Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts.
Boado RJ; Lu JZ; Hui EK; Lin H; Pardridge WM
Mol Pharm; 2016 Apr; 13(4):1385-92. PubMed ID: 26910785
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
[TBL] [Abstract][Full Text] [Related]
17. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
18. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
Zhou QH; Boado RJ; Pardridge WM
J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
[TBL] [Abstract][Full Text] [Related]
19. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.
Boado RJ; Pardridge WM
Drug Metab Dispos; 2009 Dec; 37(12):2299-304. PubMed ID: 19741036
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.
Boado RJ; Lu JZ; Hui EK; Sumbria RK; Pardridge WM
Biotechnol Bioeng; 2013 May; 110(5):1456-65. PubMed ID: 23192358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
